Candel Therapeutics Reports Q3 2026 Results, $203.1 Million in Cash
Candel Therapeutics reported a Q3 2026 net loss of $21.9M, up from $11.3M a year earlier. Cash reserves were $203.1M, expected to last until Q2 2028. R&D and G&A expenses increased. The company made clinical and regulatory progress in cancer immunotherapy programs, including FDA discussions for aglatimagene in prostate cancer.
How this was made
The 30-second read
Why it matters
The widened loss and higher R&D spend may depress the stock, but the reported clinical data and FDA dialogue could offset if results are compelling.
Market read
Earnings release provides fresh data for traders; short‑term downside risk but potential upside from trial updates.
What to watch
The company’s cash runway to Q2 2028 and ongoing FDA dialogue could provide runway for future milestones.
Background
Candel Therapeutics released its Q3 2026 earnings filing, detailing financials and clinical progress across multiple cancer programs.
Ticker impact
Q3 2026 results show net loss widened to $21.9M and cash balance of $203.1M, indicating higher expenses and extended runway.
likely pressure as the market prices in the widened loss and increased expenses
The company reported a larger net loss than a year ago and higher R&D spend, which typically weighs on the stock until clinical data provide upside.
Market effects
Biotech sector may see modest pullback as earnings miss highlights cash‑burn concerns.
US biotech investors may reassess near‑term risk for similar stage companies.
Limited to investors tracking clinical‑stage immunotherapy firms.
Counterpoint
If upcoming trial data are positive, the stock could rebound despite the earnings shortfall.
Key entities
- companyCandel Therapeutics
Biotech firm developing aglatimagene immunotherapy.